Cargando…

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa

Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging, formulation, or excipients are unique characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Montero-Vilchez, Trinidad, Cuenca-Barrales, Carlos, Rodriguez-Tejero, Andrea, Martinez-Lopez, Antonio, Arias-Santiago, Salvador, Molina-Leyva, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879480/
https://www.ncbi.nlm.nih.gov/pubmed/35207280
http://dx.doi.org/10.3390/jcm11041007
_version_ 1784658901657976832
author Montero-Vilchez, Trinidad
Cuenca-Barrales, Carlos
Rodriguez-Tejero, Andrea
Martinez-Lopez, Antonio
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
author_facet Montero-Vilchez, Trinidad
Cuenca-Barrales, Carlos
Rodriguez-Tejero, Andrea
Martinez-Lopez, Antonio
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
author_sort Montero-Vilchez, Trinidad
collection PubMed
description Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging, formulation, or excipients are unique characteristics of each drug. In that way, switching from adalimumab originator to biosimilar and between biosimilars could have implications in the clinical practice. The objective of this study is to describe our clinical experience in switching from adalimumab originator to biosimilar and switching back again. A single-center retrospective cohort study was conducted that included seventeen patients with HS treated with adalimumab originator in the maintenance phase, and that achieved Hidradenitis Suppurativa Clinical Response (HiSCR), who were switched to adalimumab biosimilar for no medical reasons. The reason for the change was to improve pharmacoeconomic efficiency, following our hospital policies on biologics. Median duration with adalimumab originator treatment before switching was 48 weeks. After switching, 41.2% of patients maintained HiSCR response without additional issues, while 58.8% (10/17) reported problems after the change. Switching from adalimumab originator to biosimilar in well-controlled patients could imply problems in efficacy and adherence. Switching back to adalimumab originator appears to solve most of the problems, but some patients can lose confidence in the drug and discontinue it. It would be worthwhile to evaluate the benefit–risk ratio individually when switching an HS patient to adalimumab biosimilar.
format Online
Article
Text
id pubmed-8879480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88794802022-02-26 Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa Montero-Vilchez, Trinidad Cuenca-Barrales, Carlos Rodriguez-Tejero, Andrea Martinez-Lopez, Antonio Arias-Santiago, Salvador Molina-Leyva, Alejandro J Clin Med Article Adalimumab is currently the only biological medicine approved by the FDA for the treatment of hidradenitis suppurativa (HS). The breakout of biosimilar drugs made them more accessible due to their impact on pharmacoeconomics. However, packaging, formulation, or excipients are unique characteristics of each drug. In that way, switching from adalimumab originator to biosimilar and between biosimilars could have implications in the clinical practice. The objective of this study is to describe our clinical experience in switching from adalimumab originator to biosimilar and switching back again. A single-center retrospective cohort study was conducted that included seventeen patients with HS treated with adalimumab originator in the maintenance phase, and that achieved Hidradenitis Suppurativa Clinical Response (HiSCR), who were switched to adalimumab biosimilar for no medical reasons. The reason for the change was to improve pharmacoeconomic efficiency, following our hospital policies on biologics. Median duration with adalimumab originator treatment before switching was 48 weeks. After switching, 41.2% of patients maintained HiSCR response without additional issues, while 58.8% (10/17) reported problems after the change. Switching from adalimumab originator to biosimilar in well-controlled patients could imply problems in efficacy and adherence. Switching back to adalimumab originator appears to solve most of the problems, but some patients can lose confidence in the drug and discontinue it. It would be worthwhile to evaluate the benefit–risk ratio individually when switching an HS patient to adalimumab biosimilar. MDPI 2022-02-15 /pmc/articles/PMC8879480/ /pubmed/35207280 http://dx.doi.org/10.3390/jcm11041007 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Montero-Vilchez, Trinidad
Cuenca-Barrales, Carlos
Rodriguez-Tejero, Andrea
Martinez-Lopez, Antonio
Arias-Santiago, Salvador
Molina-Leyva, Alejandro
Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title_full Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title_fullStr Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title_full_unstemmed Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title_short Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
title_sort switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879480/
https://www.ncbi.nlm.nih.gov/pubmed/35207280
http://dx.doi.org/10.3390/jcm11041007
work_keys_str_mv AT monterovilcheztrinidad switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa
AT cuencabarralescarlos switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa
AT rodrigueztejeroandrea switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa
AT martinezlopezantonio switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa
AT ariassantiagosalvador switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa
AT molinaleyvaalejandro switchingfromadalimumaboriginatortobiosimilarclinicalexperienceinpatientswithhidradenitissuppurativa